T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells

Journal of Neuro-Oncology

Volumn 113, Issue 1, 2013, Pages 13-25

  Chaudhuri, Swapna ^a   Bhattacharya, Debanjan ^a   Singh, Manoj Kumar ^a   Chaudhuri, Suhnrita ^a   Acharya, Sagar ^a   Basu, Anjan Kumar ^a  

^a CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

Endothelial cells; Glioma angiogenesis; PI3K Akt eNOS pathway; PTEN; T11TS; VEGF signaling

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GLIOMA; NEWBORN; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

ANIMALS; ANTIGENS, CD2; BRAIN; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; IMMUNOBLOTTING; MALE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RATS; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876935575     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1095-5     Document Type: Article

References (51)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. New Eng J Med 359(5):492-507
2. Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4(3):207-218
3. Plate KH (1999) Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 58(4):313-320
4. Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367(6463):576-579
5. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15(4):297-310
6. Peddinti R et al (2007) Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 13(12):3499-3506
7. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273(46):30336-30343
8. Thakker GD, Hajjar DP, Muller WA, Rosengart TK (1999) The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 274(15):10002-10007
9. Jiang BH, Zheng JZ, Aoki M, Vogt PK (2000) Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97(4):1749-1753
10. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL (2001) PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98:4622-4627
11. Giri D, Ittmann M (1999) Inactivation of PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30(4):419-424
12. Pan JW, Zhan RY, Tong Y, Zhou YQ, Zhang M (2005) Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. J Zhejiang Univ Sci B 6(7):693-698
13. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt dependent phosphorylation. Nature 399:601-605
14. Gressett SM, Shah SR (2009) Intricacies of bevacizumab induced toxicities and their management. Ann Pharmacother 43(3):490-501
15. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88(3):339-347
16. Mukherjee J, Ghosh A, Sarkar P, Mazumdar M, Banerjee C, Chaudhuri S (2005) Immunotherapy with T11TS/SLFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status. Anticancer Res 25(4):2905-2919
17. Acharya S, Chatterjee S, Kumar P, Bhattacharjee M, Chaudhuri S, Chaudhuri S (2009) Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3). Anticancer Drugs 21(1):53-64
18. Bhattacharjee M, Acharya S, Ghosh A, Sarkar P, Chatterjee S, Kumar P, Chaudhuri S (2008) Bax and Bid act in synergy to bring about T11TS mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation. Int Immunol 20(12):1489-1505
19. Kumar P, Acharya S, Chatterjee S, Kumari A, Chaudhuri S, Singh MK, Ghosh SN, Chaudhuri S (2012) Immunomodulatory role of TIITS in respect to cytotoxic lymphocytes in four grades of human glioma. Cell Immunol 276(1-2):176-186
20. Hunig T, Mitnacht R, Tiefenthaler G, Kohler C, Miyasaka M (1986) T11TS, the cell surface molecule binding to the "erythrocyte receptor" of T lymphocytes: cellular distribution, purification to homogeneity and biochemical properties. Eur J Immunol 16(12):1615-1621
21. Hunig T (1985) The cell surface molecule recognized by the erythrocyte receptor of T lymphocyte: identification and partial characterization using a monoclonal antibody. J Exp Med 162:890-901
22. Sarkar P, Bhattacharjee M, Acharya S, Ghosh A, Tripathi SK, Chaudhuri S (2007) Acute toxicity studies of T11TS: a glycopeptide with antineoplastic effects against glioma. Toxicol Int 14(1):47-56
23. Sarkar P, Bhattcharjee M, Acharya S, Das Gupta S, Guha D, Sadhu M, Chaudhuri S (2010) Subacute toxicity study of T11TS, a novel immunotherapeutic glycopeptide against glioma. Adv Pharmacol Toxicol 11(1):1-10
24. Mukherjee J, Sarkar S, Begum Z, Dutta S, Ghosh A, Chaudhuri S, Chaudhuri S (2002) Preclinical Changes in immunoreactivity and cellular architecture during the progressive development of intracranial neoplasms and an immunotherapeutic schedule with a novel biological response modifier, the T11TS/S-LFA3 Asian Pac J. Cancer Prev 3(4):325-337
25. Mukherjee J, Sarkar S, Ghosh A, Dutta Gupta AK, Chaudhuri S, Chaudhuri S (2004) Immunotherapeutic effects of T11TS/SLFA-3 against nitrosocompound mediated neural genotoxicity. Toxicol Lett 150(3):239-257
26. Lantos PL (1993) Chemical induction of tumors in nervous system. In: Thomas GT (ed) Neurooncology. Churchill Livingstone, New York, London, pp 85-107
27. Abbott NJ, Hughes CCW, Revest PA, Greenwood J (1992) Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 103:23-37
28. Beijnum JR, Rousch M, Castermans K, Linden E, Griffioen A (2008) Isolation of endothelial cells from fresh tissues. Nat Protoc 3(6):1085-1091
29. Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 141(7):2407-2412
30. Waltenberger J, Claessonwelsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995
31. Yoshida A, Anand-Apte B, Zetter BR (1996) Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 13(1-2):57-64
32. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14(5):381-395
33. Onishi M, Ichikawa T, Kurozumi K, Date I (2011) Angiogenesis and invasion in glioma. Brain Tumor Pathol 28:13-24
34. Siemerink MJ, Klaassen I, Vogels IM, Griffioen AW, Van Noorden CJ, Schlingemann RO (2012) CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis 15(1):151-163
35. Wang D, Stockard CR, Harkins L, Lott P, Salih C, Yuan K, Buchsbaum D, Hashim A, Zayzafoon M, Hardy RW, Hameed O, Grizzle W, Siegal GP (2008) Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem 83(3):179-189
36. Guangqi E, Cao Y, Bhattacharya S, Dutta S, Wang E, Mukhopadhyay D (2012) Endogenous vascular endothelial growth factor (VEGF): A maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription. J Biol Chem 287(5):3029-3041
37. Waters JD, Sanchez C, Sahin A, Futalan D, Gonda DD, Scheer JK, Akers J, Palanichamy K, Waterman P, Chakravarti A, Weissleder R, Morse B, Marsh N, Furfine E, Chen CC, Carvajal I, Carter BS (2012) CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. J Neurooncol 110(1):37-48
38. Fujii M, Inoki I, Saga M, Morikawa N, Arakawa K, Inaba S, Yoshioka K, Konoshita T, Miyamori I (2012) Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. J Steroid Biochem Mol Biol 129(3-5):145-152
39. Meissner M, Doll M, Hrgovic I, Reichenbach G, Konig V, Hailemariam-Jahn T, Gille J, Kaufmann R (2011) Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. Journal of Investigative Dermatology 131(6):1356-1364
40. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Manuel Deprez M (2003) Vascular endothelial growth factor expression correlates with matrix metalloproteinases Mt1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 106(6):848-855
41. Dance M, Montagner A, Yart A, Masri B, Audigier Y, Perret B, Salles JP, Raynal P (2006) The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase. J Biol Chem 281(32):23285-23295
42. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer 2(7):489-501
43. Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H (2009) PTEN regulates angiogenesis through PI3 K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 331(1-2):161-171
44. Xiao D, Li M, Herman-Antosiewicz A, Antosiewicz J, Xiao H, Lew KL, Zeng Y, Marynowski SW, Singh SV (2006) Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGFR-2. Nutr Cancer 55(1):94-107
45. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC (1999) Regulation of endothelium derived nitric oxide production by the protein kinase Akt. Nature 399(6736):597-601
46. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, de Montellano PR, Kemp BE, Pearson RB (1999) The Akt kinase and AMP kinases signal directly to endothelial nitric oxide synthase. Curr Biol 9(15):845-848
47. Kawasaki K, Smith RS Jr, Hsieh C, Sun J, Chao J, Liao JK (2003) Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol 23(16):5726-5737
48. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, Dimmeler S (2002) Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 16(7):706-708
49. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054-H1058
50. Mukherjee J (2004) Characterization of T11TS/SLFA-3 and its application as an immunomodulatory adjunct in brain tumor therapy: an immunomolecular and genetic approach in animal models. PhD Dissertation, University of Calcutta
51. Tiefenthaler G, Dustin ML, Springer TA, Hünig T (1987) Serologic cross-reactivity of T11 target structure and lymphocyte function-associated antigen 3. Evidence for structural homology of the sheep and human ligands of CD2. J Immunol 139(8):2696-2701